By Iain Gilbert
Date: Monday 07 Jan 2019
LONDON (ShareCast) - (Sharecast News) - Ultrasound software developer Medaphor warned investors on Monday that losses looked likely to have widened in its last trading year despite improved revenues.
Medaphor, which reported 27% higher revenues of £5.3m to £5.4m, also expected adjusted operating losses to have widened roughly 76% year-on-year to £3m.
The AIM-listed outfit said the loss was principally a result of around £1.5m in research and development expenses stemming from its investment into its clinical artificial intelligence division.
MedaPhor received £4.86m in December as a result of a placing and open offer - giving it a year-end cash balance of £5.5m.
As of 1035 GMT, Medaphor shares had slipped 3.23% to 7.50p.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 8.85p |
Change Today | -0.35p |
% Change | -3.80 % |
52 Week High | 15.80 |
52 Week Low | 8.00 |
Volume | 30,109 |
Shares Issued | 326.87m |
Market Cap | £28.93m |
RiskGrade | 164 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
11:50 | 30,000 @ 9.00p |
10:36 | 109 @ 9.10p |
You are here: research